摘要
目的:观察长春瑞滨(vinorelbine,NVB)联合吉西他滨(gemcitabine,GEM)治疗蒽环类和紫杉类药物耐药的转移性乳腺癌(anthracycline-and taxane-refractory metastatic breast cancer,ATRMBC)患者的疗效和不良反应。方法:采用NVB联合GEM方案(GN方案)治疗41例ATRMBC患者,NVB25mg/m2静脉推注,第1、8天;GEM1000mg/m2静脉滴注,第1、8天;21d为1个周期,最多接受6个周期的化疗。结果:41例患者共完成159个周期的化疗,中位化疗周期为4个周期。完全缓解1例(2.4%),部分缓解14例(34.2%),稳定18例(43.9%),进展8例(19.5%);客观有效率36.6%(95%CI:21.9～51.3);平均随访16.4个月,中位疾病进展时间6.1个月,中位生存期16.2个月。结论:NVB联合GEM是治疗ATRMBC的有效方案,患者对不良反应能够耐受。
Objective ： To evaluate the clinical efficacy and adverse reaction induced by vinorelbine （NVB） combined with gemeitabine （GEM） for patients with anthracyeline- and taxane-refraetory metastatic breast cancer （ATRMBC）. Methods： Forty-one ATRMBC patients were enrolled in this study. They received a combined therapy including NVB and GEM （GN regimen）. NVB was intravenously infused at 25 mg/m2 and GEM was intravenously infused at 1 000 mg/m2 on day 1 and day 8. Twenty-one days were regarded as one cycle. Maximum 6 cycles were given. Results： Forty-one patients completed 159 cycles of chemotherapy with a median number of 4 cycles per patient. One patient （2.4%） achieved a complete response, 14 patients （34.2%） had a partial response, with an overall objective response rate of 36.6% [95% confidence interval（95% CI） ：21.9-51.3 ]. Stable disease was documented in 18 patients （43.9%） while progressive disease occurred in 8 patients （ 19.5% ）. After average follow-up for 16.4 months, the median time to progression was 6.1 months, and the median overall survival time was 16.2 months. Conclusion：NVB combined with GEM may be effective for ATRMBC patients. The adverse reaetion could be tolerated by patients.
出处
《肿瘤》
CAS
CSCD
北大核心
2009年第4期386-388,共3页
Tumor
关键词
乳腺肿瘤
药物疗法
联合
药物耐受性
Breast neoplasms
Drug therapy, combination
Drug tolerance
作者简介
董宁宁（1983-），女（汉族），硕士研究生
Correspondence to：WANG Ming-yu E-mail ： lmwmy@ 163. com
